SecBot SecBot
8-K ·Filed Apr 3, 2026

INM

InMed Pharmaceuticals Inc.
NEUTRAL
Impact 3/10
Horizondays Processed7mo ago SEC0001213900-26-039943
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

Monitor for actual sales under this ATM program, as the filing itself is procedural. The small offering size suggests a need for capital but is not immediately dilutive unless fully utilized.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$0.6950
T+0 close · Apr 3, 2026 · via day close
Latest settled
+128.78%
T+60 · $1.59
Vs SPY
+115.31%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 6 $0.6950entry
  2. T+1 · 7mo ago −2.16%α −2.22% · $0.6800
  3. T+5 · 7mo ago +2.59%α −1.54% · $0.7130
  4. T+20 · 7mo ago +7.63%α −1.36% · $0.7480
  5. T+60 · 5mo ago +128.78%α +115.31% · $1.59
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

InMed Pharmaceuticals filed a prospectus supplement to its shelf registration statement to sell up to $1,213,648 worth of common shares through an at-the-market offering with H.C. Wainwright & Co. This is a routine capital raise under an existing agreement.

Key Facts

  • InMed Pharmaceuticals filed a prospectus supplement on April 3, 2026, to sell up to $1,213,648 of common shares.
  • The offering is conducted through an at-the-market (ATM) agreement with H.C. Wainwright & Co., originally dated April 7, 2022, and amended June 27, 2024.
  • The shares are being offered under a shelf registration statement (Form S-3, File No. 333-294503) declared effective on March 30, 2026.
  • The filing includes a legal opinion confirming the legality of the securities being registered.

Financial Impact

Up to $1,213,648 in gross proceeds from the sale of common shares, representing a small potential dilution given the company's $2M market cap.

dilutionequitycash

Risk Factors

  • Potential share dilution if the full amount is sold.
  • Downward pressure on stock price if sales occur in a weak market.
  • Use of proceeds not specified, creating uncertainty about how funds will be deployed.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001213900-26-039943
Document: ea028498901ex5-1.htm0001213900-26-039943
Document: 0001213900-26-039943-index-headers.html0001213900-26-039943
Document: 0001213900-26-039943-index.html0001213900-26-039943
Document: 0001213900-26-039943.txt0001213900-26-039943

US Market Status

Market Closed · Opens in 6h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 3, 2026